Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline consumer boss outlines commitment to OTC therapies

GlaxoSmithKline consumer boss outlines commitment to OTC therapies

16th December 2016

GlaxoSmithKline's consumer healthcare chief executive Brian McNamara has outlined some of the steps the company will take to increase its investment in the over-the-counter (OTC) medicines market.

In an interview with Business Insider, Mr McNamara highlighted the company's belief in the broad benefits of expanding the availability of affordable OTC medicines for healthcare systems worldwide.

He stated that the organisation's current strategy involves switching a prescription drug to OTC status at least once every five years, pointing to the example of the allergy therapy Flonase as an example of a product that has successfully made this transition.

This is beneficial not only for GlaxoSmithKline but also for patients, as it makes treatments they rely upon more accessible and removes the need for hospital visits.

Mr McNamara said: "It plays a really critical role in obviously helping consumers to take control of their own healthcare, but also as a very real and quantifiable benefit to the overall healthcare system."

The new GlaxoSmithKline consumer head was appointed to the role in October, following the confirmation of his predecessor Emma Walmsley's selection as GlaxoSmithKline's new chief executive officer.

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801830115-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.